<DOC>
	<DOCNO>NCT01303783</DOCNO>
	<brief_summary>The purpose study determine blood pressure lower response various dose combination nifedipine GITS candesartan compare treatment component ( monotherapy ) placebo ( look-alike tablet without active ingredient ) . The drug - nifedipine GITS candesartan - investigate currently approve use patient essential hypertension alone together antihypertensive drug ( combination therapy ) , optimal dose nifedipine GITS candesartan use together treatment essential hypertension establish yet . In study patient treat various dos nifedipine GITS and/or candesartan placebo . These different regimen administer day assess base blood pressure lower effect ( mean sit diastolic blood pressure ) subject mild moderate essential hypertension .</brief_summary>
	<brief_title>Study Nifedipine GITS Candesartan Combination Compared Monotherapy Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Male female subject 18 year old . Female subject must either postmenopausal one year , surgically sterile , use effective contraceptive method . Hormonal contraceptive use disallow . Subjects must mild moderate essential hypertension ( Grade 1 2 WHO classification ) measure calibrated standard sphygmomanometer . ( MSDBP ≥90 mmHg &lt; 110 mmHg Visit 1 ( placebo runin ) , MSDBP ≥95 mmHg &lt; 110 mmHg visit 2 ( randomization ) Subjects must absolute difference MSDBP le 10 mmHg Visit 1 ( placebo run ) Visit 2 ( randomization ) . Severe hypertension ( Grade 3 WHO classification ; MSDBP ≥110 mmHg and/or MSSBP ≥ 180 mmHg ) Inability washout antihypertensive drug ( even prescribe another indication ) safely period 14 week . History hypertensive retinopathy know KeithWagener Grade III IV History hypertensive encephalopathy Cerebrovascular ischemic event ( stroke , transient ischemic attack [ TIA ] ) within previous 12 month History intracerebral hemorrhage subarachnoid hemorrhage Evidence secondary hypertension coarchation aorta , pheochromocytoms , hypersaldosteronism , etc . Type I diabetes mellitus ( DM ) poorly control DM Type II evidence glycosylated hemoglobin [ HbA1C ] great 9 % visit 1 . Allergies know intolerance one investigational drugs/drug class one ingredients Any history heart failure , New York Heart Association ( NYHA ) classification III IV Severe coronary heart disease manifest history myocardial infarction unstable angina last 6 month prior visit 1 . Clinically significant cardiac valvular disease History malignancy last 5 year , exclude basal skin cancer Uncorrected hypokalemia hyperkalemia : potassium outside 3.05.0 mmol/L Surgical medical condition might alter metabolism , excretion distribution absorption drug 1 . Gastrointestinal disease surgery result potential malabsorption 2 . Severe gastrointestinal tract narrowing ; kock pouch ( ileostomy proctocolectomy ) 3 . Cholestasis biliary obstruction history pancreatic injury clinical significant increase lipase , amylase , bilirubin . 4 . Liver disease AST/ALT level &gt; 3 x ULN 5 . Renal insufficiency , define eGFR &lt; 50 mL/min ( compute use CockroftGault formula ) , hemodialysis Investigation trial participation receipt investigational study drug within last month Previous assignment treatment study Female subject pregnant lactating . Subjects night employment ( night shift ) . Subjects aortic aneurysm , opinion investigator , unsuitable enrol study . Thought investigator reason unsuitable participation clinical study Systemic use know cytochrome P4503A4 inhibitor ( e.g cimetidine , antihuman immunodeficiency virus [ HIV ] protease inhibitor e.g . ritonavir , azole antimycotic eg . ketoconazole , ) inducer ( e.g rifampicin , antiepileptic drug eg . phenytoin , carbamazepine phenobarbitone ) P4503A4 substrates ( e.g quinidine , digoxin , tacrolimus ) Present severe rhythm conduction disorder : Atrial fibrillation Second third degree heart block without pacemaker . Baseline QTc &gt; 450 msec History noncompliance , alcoholism drug abuse opinion investigator compromise successful completion study . If difference great 20 mmHg SBP 10 mmHg DBP present 3 consecutive BP reading , subject exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Nifedipine GITS</keyword>
	<keyword>Candesartan</keyword>
	<keyword>mild moderate Hypertension</keyword>
	<keyword>Combination therapy</keyword>
</DOC>